Does Methotrexate Increase Cancer Risk Overall?
Methotrexate, used for rheumatoid arthritis, psoriasis, and some cancers, carries a small increased risk of certain malignancies, mainly lymphomas and skin cancers. Large cohort studies show no broad elevation in overall cancer incidence; a Danish registry analysis of over 13,000 rheumatoid arthritis patients found standardized incidence ratios (SIR) near 1.0 for most solid tumors.[1] Risks stem from its DNA synthesis inhibition, potentially promoting mutagenesis in rapidly dividing cells.
What Lymphomas Are Linked?
Methotrexate is associated with Epstein-Barr virus (EBV)-positive B-cell lymphomas, often regressing after drug withdrawal. In rheumatoid arthritis patients, SIR for lymphoma is 1.9–2.4, with odds ratios up to 3.5 in high-dose users.[2][3] These are typically diffuse large B-cell lymphomas or Hodgkin-like subtypes. Risk rises with cumulative dose >3g and duration >2 years; EBV negativity lowers regression rates post-discontinuation.
Skin Cancer Risks Explained
Non-melanoma skin cancers (NMSC), especially squamous cell carcinoma, show elevated risk (SIR 1.5–2.0) due to immunosuppression and UV photosensitivity.[1][4] Melanoma risk is inconsistent, with some meta-analyses reporting no increase (OR 1.1, 95% CI 0.8–1.5).[2] Psoriasis patients on methotrexate face higher NMSC rates, compounded by prior PUVA therapy.
Does It Cause Solid Tumors Like Lung or Breast Cancer?
No strong evidence links methotrexate to lung, breast, or colorectal cancers. Rheumatology cohorts report SIRs of 0.9–1.1 for these.[1][3] Paradoxically, lower rates occur in rheumatoid arthritis patients, possibly due to surveillance bias or anti-inflammatory effects offsetting risks.
Risks in Cancer Patients vs. Non-Cancer Uses
In leukemia or osteosarcoma treatment, high-dose methotrexate (bolus >1g/m²) is standard and not linked to secondary cancers beyond baseline chemotherapy risks. Low-dose weekly regimens (7.5–25mg) for autoimmune diseases drive the lymphoma signal.[5] Pediatric use shows no excess solid tumors long-term.
How Does Duration and Dose Affect Risk?
Risk scales with exposure: lymphomas emerge after 2–5 years at doses >10mg/week; NMSC after 5+ years.[2] Guidelines recommend folate supplementation and skin checks to mitigate.[4]
Comparison to Other DMARDs
Methotrexate's lymphoma risk exceeds TNF inhibitors (SIR 1.3–1.8) but is similar to azathioprine.[3] Combination with biologics may amplify it slightly (OR 2.0).[2]
[1] Habel et al., Arthritis Rheum 2010 (PubMed)
[2] Mariette et al., Ann Rheum Dis 2017 (PubMed)
[3] Hellgren et al., Arthritis Rheumatol 2017 (PubMed)
[4] Gouverneur et al., JAMA Dermatol 2017 (PubMed)
[5] Methotrexate prescribing information, FDA label